Last updated: May 29, 2026

Application No. 17/636,699

ANTI-CD19 ANTIBODIES AND USES THEREOF

Non-Final OA

Filed

Feb 18, 2022

Priority

Aug 19, 2019 — provisional 62/888,724 +1 more

Examiner

HOPKINS, SAMANTHA LAKE

Art Unit

1641

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Elpis Biopharmaceuticals

OA Round

1 (Non-Final)

This examiner grants 58% of cases after interview

— +61.5% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 38 resolved cases, 2023–2026

Examiner Intelligence

HOPKINS, SAMANTHA LAKE View full profile →

Grants 58% of resolved cases

Career Allowance Rate

22 granted / 38 resolved

-2.1% vs TC avg

Strong +62% interview lift

Without

With

+61.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 9m

Avg Prosecution

23 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

42.2%

+2.2% vs TC avg

§102

6.9%

-33.1% vs TC avg

§112

16.7%

-23.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 38 resolved cases

Prosecution Timeline

Feb 18, 2022

Application Filed

Sep 11, 2025

Non-Final Rejection mailed

Apr 20, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

17/631,641

Patent 12630627

FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF

4y 3m to grant Granted May 19, 2026

17/609,053

Patent 12617866

HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF

4y 6m to grant Granted May 05, 2026

17/618,922

Patent 12599650

INHIBITIONS OF SIRP-GAMMA FOR CANCER TREATMENT

4y 4m to grant Granted Apr 14, 2026

17/616,274

Patent 12595303

ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACI

4y 4m to grant Granted Apr 07, 2026

17/615,832

Patent 12590149

ANTIBODY AND BISPECIFIC ANTIBODY TARGETING LAG-3 AND USE THEREOF

4y 4m to grant Granted Mar 31, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

58%

Grant Probability

99%

With Interview (+61.5%)

3y 9m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 38 resolved cases by this examiner. Grant probability derived from career allowance rate.